DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Rubicon Research Limited (RUBICON) share price today?

Rubicon Research Limited (RUBICON) is trading at ₹1,531.7 on the NSE, up 3.70% on the day. Source: DocStoX.

What is the PE ratio of Rubicon Research Limited?

Rubicon Research Limited has a price-to-earnings (PE) ratio of 98.7 in the Healthcare sector.

What is the market capitalisation of Rubicon Research Limited?

Rubicon Research Limited has a market capitalisation of approximately ₹25,016 crore.

Is Rubicon Research Limited a profitable company?

Rubicon Research Limited generates a return on equity of 19.1% with a net profit margin of 14.1%. That is a strong return on shareholder capital.

What is the 52-week high and low of RUBICON?

Rubicon Research Limited (RUBICON) has traded between ₹570.75 and ₹1,899 over the past 52 weeks, against a current price of ₹1,531.7.

Does Rubicon Research Limited pay a dividend?

Yes. Rubicon Research Limited currently offers a dividend yield of 0.08%. Dividend payments depend on the board's declaration each year.

Rubicon Research Limited

₹1,531.70▲ +54.60 (+3.70%)

RUBICON·NSE·Healthcare

Market Cap

25016.01 Cr

PE Ratio

98.69

Volume

69,115

Day High - Low

1533.10 - 1468.00

52W High-Low

1899.00 - 570.75

₹1,531.70▲ +54.60 (+3.70%)

Market Cap25016.01 Cr

PE Ratio98.69

Volume69,115

Day High - Low1533.10 - 1468.00

52W High-Low1899.00 - 570.75

Rubicon Research Limited (RUBICON): company summary

The company's business is improving, with annual revenue rising 36.6% and net profit surging 84.1%.

Rubicon Research Limited (RUBICON) is a mid-cap Healthcare company valued at ₹25,016 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Rubicon Research Limited last traded at ₹1,531.7, up 3.70% on the day.
Recent developments: On 2026-08-07, the company announced a dividend of ₹1.50 per share, ex-date. Promoter holding fell by 0.10 percentage points in the latest quarter, while domestic institutional holding dropped 0.59 percentage points. The company's revenue grew at a 64.5% CAGR over the past three years and 41.0% over five years, with net profit growing at 51.4% CAGR over five years.
Financial performance: The company's business is improving, with annual revenue rising 36.6% and net profit surging 84.1%. The latest quarter saw revenue jump 51.8% and net profit climb 97.2% compared to the same quarter a year earlier. Net profit margin expanded 3.6 percentage points to 14.1%, while return on equity and return on capital employed remained strong at 19.1% and 22.7%, respectively.
Valuation multiples: The stock trades at 98.7 times earnings, a premium to the Healthcare median of 32.0, 23.00 times book value. It yields 0.1%.
Things to watch: The stock is 14.1% below its 52-week high, and promoter holding decreased slightly in the latest quarter. Domestic institutional holding also fell by 0.59 percentage points. The company's net profit swung from a loss to a profit over the past three years, but the recent quarter's net profit growth was driven by higher revenue rather than margin expansion.
Where it stands: The company has delivered strong revenue and profit growth, with the latest quarter showing a sharp increase in both metrics. The stock's price is significantly below its 52-week high, and promoter holding has declined slightly. The most significant movement was in the latest quarter's net profit, which rose 97.2% year-over-year.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

5.6/10

Fair

Fair Value

ROE

19.14%

Strong

P/E

98.69x

Expensive

Debt / Equity

0.24

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY 500NIFTY SMALLCAP 250

Day₹1468

₹1533

52W₹570.75

₹1899

DocStoX take

Supported by growth (8.5) and momentum (7.5), but held back by valuation (0.0). Growth looks strong at 8.5, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

5.6

/10

Fair

Quality

Solid

ROE 19.1%

Valuation

Expensive

P/E 98.7×

Growth

Strong

Revenue +41.0% 5Y CAGR

Risk

Moderate

D/E 0.24

Momentum

Strong

72% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹1,532

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹25,016 Cr

52W High / Low

₹1899 / ₹571

Dividend Yield

0.08%

Promoter Holding

59.76%

EPS (TTM)

₹15.52

Book Value

₹78.07

Key highlights

Profit compounding 51% a year
Revenue compounding 41% a year
Low leverage — D/E 0.24
Loss-making in some of the last 5 years
Valuation is weak (0.0/10)

4 Positives3 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Rubicon Research Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Rubicon Research Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Rubicon Research Limited with peers

Rubicon Research Limited vs Sun Pharmaceutical Industries Limited Rubicon Research Limited vs Divi's Laboratories Limited Rubicon Research Limited vs Torrent Pharmaceuticals Limited Rubicon Research Limited vs Apollo Hospitals Enterprise Limited Rubicon Research Limited vs Zydus Lifesciences Limited Rubicon Research Limited vs Laurus Labs Limited

Related tools & concepts

Value Rubicon Research Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

RUBICON newsLatest coverage & filings Open screenerFilter the whole market